Are Investors Undervaluing Catalent, Inc. (NYSE:CTLT) By 24%?
De Motu Cordis (DMC) Announces Plans for the Next Stage of Development for DMC-IH1, an Inhaled Epinephrine Drug Device Combination Product
Catalent (CTLT) Expands Its Facility Capabilities in Germany
Catalent Completes $25 Million Expansion of Its Clinical Supply Facility in Schorndorf, Germany
Catalent Price Target Maintained With a $63.50/Share by RBC Capital
RBC Capital Reiterates Sector Perform on Catalent, Maintains $63.5 Price Target
RBC Capital Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $63.5
Analysts Conflicted on These Healthcare Names: Lantheus (LNTH) and Catalent (CTLT)
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
Unusual Options Activity: CTLT, STX and Others Attract Market Bets, CTLT V/OI Ratio Reaches 250.0
Catalent Is Maintained at Equal-Weight by Barclays
Catalent Analyst Ratings
Express News | Catalent : Barclays Raises Target Price to $63 From $47
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Raises Target Price to $63
Barclays Adjusts Catalent Price Target to $63 From $47
Sarepta Cut to Neutral at Citi on Risks to Valuation
Sarepta's Expanded Approval Unlikely To Influence Novo Holdings' Acquisition of Catalent, But Provides Investor Protection Amid Uncertainty
Catalent Gains After Sarepta's Elevidys Gets Label Expansion
Pharmaceutical Contract Manufacturing Market Report 2024-2030: Trends, Opportunities and Competitive Analysis Featuring Thermo Fisher Scientific, Catalent, Lonza, Almac Group, and Recipharm
Express News | Shares of Contract Drug Manufacturer Catalent up 3.3% After FDA's Expanded Use Nod for Sarepta's Duchenne Gene Therapy